127 related articles for article (PubMed ID: 1659980)
1. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Bremer K; Uhlenbusch R
Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
[TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Chevallier B
Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
[TBL] [Abstract][Full Text] [Related]
5. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
7. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. The Granisetron Study Group.
Bremer K
Eur J Cancer; 1992; 28A(6-7):1018-22. PubMed ID: 1320907
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
Marty M
Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
[TBL] [Abstract][Full Text] [Related]
9. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
[TBL] [Abstract][Full Text] [Related]
10. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
11. Granisetron-dexamethasone combination for multiple day cisplatin.
Pronzato P; Losardo PL; Vaira F; Vigani A; Landucci M; Ghio E
Anticancer Res; 1995; 15(5B):2261-3. PubMed ID: 8572634
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
13. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
J Cancer Res Clin Oncol; 1993; 119(9):555-9. PubMed ID: 8392077
[TBL] [Abstract][Full Text] [Related]
14. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
15. Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.
Diehl V
Eur J Cancer; 1992; 28A Suppl 1():S21-8. PubMed ID: 1320916
[TBL] [Abstract][Full Text] [Related]
16. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
17. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1998 Oct; 71(1):113-5. PubMed ID: 9784330
[TBL] [Abstract][Full Text] [Related]
18. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Soukop M
Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
